Table 2: Sixty human tumor cell lines anticancer screening data of curcumin analogues (1–14).

Panel/cell lineGrowth percent in one-dose assay
12356810111213

Leukemia
 CCRF-CEM−4.544.456.820.870.441.54−5.123.5216.721.68
 HL-60(TB)−24.28−20.94−21.36−28.92−28.17−30.36−42.20−23.8961.333.67
 K-5622.27−7.300.22−3.902.29−7.18−15.523.6242.035.49
 MOLT-4−4.57−2.00−3.56−17.670.11−20.68−39.87−6.5336.344.17
 RPMI-8226−22.312.913.32−11.32−14.46−16.73−33.6014.2562.492.88
 SR−17.721.522.531.44−14.65−2.07−13.89−4.7727.24−7.94
Non-small-cell lung cancer
 A549/ATCC8.754.0312.025.904.71−3.988.4041.7371.6810.09
 EKVX17.6816.8526.87−17.6720.29−14.72−38.7930.5571.6022.16
 HOP-62 8.3917.0630.22−7.7811.62−35.66−67.7343.5370.774.85
 HOP-92 −14.42−4.70−3.45NT−15.38−27.02NTNT33.70−21.24
 NCI-H226−3.725.7315.88−4.32−0.89−3.70−8.1938.4876.2011.70
 NCI-H23 −25.823.1610.74−12.87−10.41−26.09NT17.6662.85−2.79
 NCI-H322M NT22.1327.3212.63NT8.13−3.6439.48NTNT
 NCI-H460 7.399.418.354.4310.141.87−0.079.1569.705.54
 NCI-H522−18.66−4.94−6.0410.89−19.346.31−30.234.2054.59−41.31
Colon cancer
 COLO 205−73.497.578.7359.43−25.81−65.55−84.0523.8751.81−50.38
 HCC-29982.834.556.929.752.194.285.8240.9470.990.93
 HCT-1161.164.614.952.151.601.48−5.836.9034.750.33
 HCT-1515.057.8610.636.6415.223.84−3.3816.2181.7929.55
 HT29−34.95−11.07−41.84−33.57−22.35−38.54−52.390.38−6.41−76.24
 KM120.093.532.440.08−1.13−9.35−27.964.9829.26−29.25
 SW-6206.999.5610.522.038.12−10.94−22.7220.8643.581.86
CNS cancer
 SF-268−6.3813.8720.126.57−11.503.80−12.5227.9748.193.56
 SF-2952.83−21.89−21.61−55.320.53−51.02−71.47−29.6892.76−5.25
 SF-5394.060.163.68−16.585.95−19.58−39.794.0269.0211.95
 SNB-1915.499.2520.154.4220.272.451.1836.2282.6023.19
 SNB-75−4.7118.7526.93−12.609.53−30.53−53.1827.2844.325.50
 U2512.334.3113.38−1.596.19−12.27−1.4735.0655.642.97
Melanoma
 LOX IMVI1.223.044.00−20.871.89−29.79−37.119.2949.04−16.09
 MALME-3M8.273.949.15−16.8017.27−21.70−38.9823.4353.57−28.85
 M140.264.042.69−21.862.30−38.14−55.955.4275.46−26.13
 MDA-MB-4354.082.46−2.32−25.94−1.64−40.91−67.34−30.5356.89−8.12
 SK-MEL-2−12.27−23.52−27.07−25.00−13.98−27.22−48.11−0.3381.15−21.01
 SK-MEL-2812.1012.7216.707.8713.225.57−6.7328.6450.899.55
 SK-MEL-5−23.76−29.66−8.36−73.861.16−83.44−86.52−1.9170.74−18.40
 UACC-2571.283.1113.66−15.894.80−21.4216.0387.1362.46−1.90
 UACC-621.044.062.01−37.420.49−48.47−84.393.4863.31−57.66
Ovarian cancer
 IGROV1−6.589.9317.414.574.76−1.75−21.1824.9593.123.42
 OVCAR-3−26.77−10.973.89−26.44−34.15−37.33−46.9212.5559.34−7.57
 OVCAR-46.5913.2535.559.2616.087.874.4949.8053.9818.31
 OVCAR-513.1810.9431.320.8820.53−4.24−7.7484.49101.675.83
 OVCAR-81.50−19.830.47−44.00−2.98−34.66−13.1127.7358.719.33
 NCI/ADR-RES20.8317.4627.9112.0120.507.643.1828.1390.6639.32
 SK-OV-3−33.32−0.37−18.66−31.16−29.09−63.58−53.0816.5571.63−17.39
Renal cancer
 786-0−14.80−2.20−6.90−32.92−1.18−59.07−76.679.9182.57−58.93
 A498−11.83−0.6031.49−13.6512.02−14.70−25.1756.4162.76−56.92
 ACHN2.839.2920.225.7316.125.252.7725.1289.3613.46
 CAKI-17.290.13−7.81−39.108.65−36.63−60.45−34.7788.6119.24
 RXF 393−50.32−53.60−43.84−57.61−47.46−67.29−70.03−3.8323.75−63.92
 SN 12C14.209.0017.952.0618.300.47−3.1114.2362.2622.14
 TK-1016.1523.1038.1224.0428.5515.866.1865.02102.7421.38
 UO-31−34.842.7114.05−16.950.97−38.74−44.6423.8654.253.16
Prostate cancer
 PC-36.544.249.01−14.268.08−10.82−33.1412.9261.0112.99
 DU-1451.2311.666.77−11.842.20−26.64−45.7428.8780.3713.04
Breast cancer
 MCF74.415.369.492.066.30−3.78−5.7120.2252.107.59
 MDA-MB-231/ATCC17.7114.3533.6112.2419.9410.255.2339.6954.193.39
 HS 578T−4.718.2320.04−12.92−15.97−14.33−12.983.5953.91−1.00
 BT-549−26.40−14.35−8.33−24.17−23.00−33.81−47.1614.4955.03−24.41
 T-47D4.5518.5031.152.295.65−22.55−23.9348.9959.141.57
 MDA-MB-468−24.19−26.40−14.60−27.56−29.14−30.34−31.862.976.34−35.04

Mean4.661.817.2312.250.6619.1928.7119.0359.945.46

Range94.3276.7081.9697.9076.0199.30102.55121.90109.15115.56

NT: not tested.